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Abstract: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a highly conserved pleiotropic neuropeptide that functions as a 
neurotransmitter, neuromodulator and neurotrophic factor. Accumulating evidence implicates PACAP as an important regulator of both 
central and/or peripheral components of the stress axes, particularly exposure to prolonged or traumatic stress. Indeed, PACAP and its 
cognate receptors are widely expressed in the brain regions and peripheral tissues that mediate stress-related responses. In the sym-
pathoadrenomedullary system, PACAP is required for sustained epinephrine secretion during metabolic stress. It is likely that PACAP 
regulates autonomic function and contributes to peripheral homeostasis by maintaining a balance between sympathetic and parasympa-
thetic activity, favoring stimulation of the sympathetic system. Furthermore, PACAP is thought to act centrally on the paraventricular nu-
cleus of the hypothalamus to regulate both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Intriguingly, 
PACAP is also active in brain structures that mediate anxiety- and fear-related behaviors, and the expression of PACAP and its receptors 
are dynamically altered under pathologic conditions. Thus PACAP may influence both hard-wired (genetically determined) stress re-
sponses and gene-environment interactions in stress-related psychopathology. This article aims to overview the molecular mechanisms 
and psychiatric implications of PACAP-dependent stress responses. 
Keywords: Hypothalamic-pituitary-adrenal (HPA) axis, PACAP, paraventricular nucleus (PVN) of the hypothalamus, post-traumatic disor-
der (PTSD), psychiatric disorders, stress, sympathoadrenomedullary system, sympathetic nervous system. 
INTRODUCTION 
  Stress is defined as a state of threat, or perceived threat to ho-
meostasis and can be classified under four main categories: 1) 
physical stressors; 2) psychological stressors that reflect a learned 
response to previously experienced adverse conditions; 3) social 
stressors reflecting disturbed interactions among individuals; and 4) 
stressors that challenge cardiovascular and metabolic homeostasis 
[1, 2]. Adaptation to stressful stimuli is a priority for all organisms 
and involves the activation of specific central circuits. Adaptive 
responses are genetically and constitutionally programmed (“hard-
wired”) and are constantly modulated by environmental factors 
(“gene-environmental interaction”). Stress axes comprising the 
sympathoadrenal and sympathoneuronal systems and the hypotha-
lamic-pituitary-adrenocortical axis, respond to different types of 
stressors and exhibit stressor-specific response patterns [1-3]. 
  Neuropeptides tend to exert a long-lasting modulatory effect on 
the small-molecule neurotransmitters with which they colocalize, 
by regulating the response times of second messenger systems [4]. 
Thus, neuropeptides are important for adaptation of the nervous 
system to pathophysiological conditions. The neuropeptide, pitui-
tary adenylate cyclase-activating polypeptide (PACAP), has long 
been recognized as an important regulator of central and peripheral 
components of the stress axes, as outlined in Table 1. 
PITUITARY ADENYLATE CYCLASE-ACTIVATING 
POLYPEPTIDE (PACAP) 
  PACAP was first identified as a novel hypothalamic neuropep-
tide in 1989 by Miyata et al., based on its ability to stimulate adeny- 
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late cyclase in rat anterior pituitary cell cultures [5]. PACAP exists 
in two biologically active forms, PACAP-38 and the C-terminally 
truncated PACAP-27. PACAP-27 has an amino acid sequence 68% 
consistent with vasoactive intestinal polypeptide (VIP) and 37% 
with secretin, indicating that PACAP is a member of the VIP/glu-
cagon/growth hormone-releasing hormone (GHRH)/secretin super-
family [6]. 
  The primary structure of PACAP-38 is completely conserved 
across all mammalian species studied to date, and is virtually un-
changed between mammals, lower vertebrates and protochordates 
[7]. This structural conservation is a testimony to the vital physio-
logical role of PACAP. PACAP and the three subtypes of PACAP 
cognate receptors, PAC1, VPAC1 and VPAC2, are found in both the 
central nervous system and the periphery. In the central nervous 
system, PACAP is involved in a variety of physiological and patho-
physiological processes, including those underlying higher brain 
function, emotional and behavioral regulation and neuroprotection 
[6]. 
DISTRIBUTION OF PACAP AND ITS RECEPTORS IN 
STRESS-RELATED NEURAL SYSTEMS 
  Stress responses are mediated by specialized neural circuits in 
the limbic forebrain, hypothalamus and brainstem, which activate 
and control neuroendocrine and autonomic stress systems [1-3]. 
  In the rat, PACAP is most abundant in the hypothalamic area. 
Indeed, PACAP-immunoreactive neurons and PACAP receptors are 
primarily located in the magnocellular region of the paraventricular 
nucleus (PVN) of the hypothalamus and in the supraoptic nucleus 
of the hypothalamus, structures which produce the stress-related 
hormones, oxytocin and vasopressin [6, 8-10]. Dense PACAP-
immunoreactive fibers can be observed in the median eminence and 
in the hypothalamo-hypophysial portal system [6, 8, 9], and a 986    Current Pharmaceutical Design, 2011, Vol. 17, No. 10  Hashimoto et al. 
higher amount of PACAP has also been detected in hypophysial 
portal blood compared with peripheral blood [11]. 
  PACAP and PACAP receptors are also widely distributed in 
brain areas outside the hypothalamo-hypophysis known to be in-
volved in stress responses, including the medial prefrontal cortex, 
hippocampus, amygdala, bed nucleus of the stria terminalis (BNST) 
and adrenal gland [6, 8, 12-14]. 
 PAC1 receptor mRNA is generally the most widely and abun-
dantly expressed of the three PACAP receptor subtypes, although 
there are exceptions, for example VPAC1 receptor mRNA is abun-
dantly expressed in hippocampal pyramidal neurons [15] and 
VPAC2 receptor mRNA is abundantly expressed in the central 
amygdala [16]. 
  At a subcellular level, PACAP-immunoreactivity appears to be 
concentrated within neuronal cell bodies and dendrites. Ultrastruc-
turally, it is noteworthy that immunostaining for the PAC1 receptor 
revealed its presence on synaptic membranes [13]. 
Detailed anatomical information regarding stress responses are 
discussed in the following sections. 
PACAP-DEPENDENT STIMULATION OF THE SYM-
PATHOADRENOMEDULLARY SYSTEM 
  Many studies have focused on the role of PACAP in the sym-
pathoadrenomedullary system. Retrograde tracing studies with the 
cholera toxin B subunit have shown that PACAP is expressed in 
various hypothalamic and extrahypothalamic regions, and in the 
catecholaminergic neurons of the brain stem that innervate the PVN 
and the intermediolateral cell column of the spinal cord [17, 18]. 
Additionally, sympathetic preganglionic neurons projecting to the 
adrenal medulla contain PACAP [19, 20]. 
  PACAP is postulated to function as an "emergency response" 
cotransmitter in the sympathoadrenal axis during metabolic stress, 
by ensuring sustained secretory responses [21]. During insulin-
induced hypoglycemia, PACAP-deficient mice exhibit impaired 
long-term secretion of epinephrine due to defective compensatory 
stimulation of catecholamine biosynthesis [21]. In addition, adap-
tive thermogenesis is impaired in PACAP-deficient mice subjected 
to prolonged periods of cold stress, due to insufficient norepineph-
rine stimulation of brown adipose tissue [22]. Furthermore, synthe-
sis of adrenaline-synthesizing enzymes in the adrenal medulla is 
decreased in PACAP-deficient mice subjected to a psychological 
stressor such as restraint stress, suggesting that PACAP is a key 
neuroendocrine factor in the hypothalamus and adrenal gland [23]. 
In adrenal chromaffin cells, PACAP exerts a stimulatory effect on 
catecholamine secretion, which is associated with increased expres-
sion of catecholamine biosynthetic enzyme genes [24]. 
PACAP-DEPENDENT STIMULATION OF OTHER SYM-
PATHETIC PATHWAYS 
  The demonstration of preproPACAP within the sympathetic 
preganglionic neurons that innervate the adrenal gland, and in those 
at level C8-T10 of the spinal cord, suggests that PACAP is widely 
distributed in the sympathetic nervous system [20]. PAC1 receptor 
mRNA is intensely expressed in virtually all principal neurons of 
the sympathetic superior cervical ganglia in rat, and PACAP 
mRNA is expressed with variable intensity in approximately half of 
the principal neurons in this structure [25]. 
 In  vivo electrophysiological studies have shown that PACAP 
injected into the third ventricle activates sympathetic fibers that 
innervate brown adipose tissue, the kidneys, adrenal gland, and 
other abdominal viscera, whereas it suppresses parasympathetic 
nerve activities [26]. These results suggest that PACAP regulates 
autonomic function and contributes to peripheral homeostasis by 
maintaining a balance between sympathetic and parasympathetic 
activity [26]. 
PACAP-DEPENDENT STIMULATION OF THE HYPO-
THALAMIC-PITUITARY-ADRENAL (HPA) SYSTEM 
  Immunohistochemical studies have revealed that a significant 
proportion of PACAP-immunoreactive neurons in the PVN co-
Table 1.  PACAP-dependent Stress Responses 
Effect or Implication of PACAP  References 
BNST  Dramatic increase in PACAP and BDNF mRNA expression by chronic unpredictable stress 
Anxiogenic response induced by intra-BNST infusion of PACAP 
[38, 39] 
Amygdala  Stress-related behaviors induced by infusion of PACAP into the central nucleus of the amygdala  [42] 
HPA axis  Stimulation of CRF gene expression in the PVN 
Stimulation of pro-opiomelanocortin gene expression and adrenocorticotropin release 
Activation of vasopressin-containing neurons in the supraoptic nucleus and plasma vasopressin secretion 
Impairment of stress-induced corticosterone secretion in PACAP-deficient mice 
Acute stress-related behaviors and increased plasma corticosterone induced by intracerebroventricular injec-
tion of PACAP 
[9, 23, 28, 37] 
[5, 29-31] 
[10, 32-34] 
[23] 
[37] 
Sympathoadreno- 
medullary system 
Sustained epinephrine secretion during prolonged stress by enhancement of compensatory catecholamine 
synthesis 
[21, 23, 24] 
Automonic nervous system  Stimulation of sympathetic outflow 
Maintenance of a sympathetic–parasympathetic balance 
[26] 
PTSD  Female-specific association of the PACAP–PAC1 receptor pathway with PTSD  [51] 
BDNF: brain-derived neurotrophic factor 
BNST: bed nucleus of the stria terminalis 
HPA axis: hypothalamic-pituitary-adrenal axis 
PTSD: post-traumatic stress disorder 
PVN: paraventricular nucleus of the hypothalamus PACAP and the Stress Axes  Current Pharmaceutical Design, 2011, Vol. 17, No. 10    987 
express corticotropin-releasing factor (CRF) [9]. Electron micro-
scopic studies have revealed the presence of synapses between 
PACAP-containing terminals and CRF-perikarya and -dendrites 
[27]. PACAP injected intracerebroventricularly activates CRF gene 
expression in the rat PVN [28], while intravenously infused 
PACAP induces a dose-dependent increase in serum adrenocortico-
tropin levels in human [29]. In vitro, PACAP increases adrenocorti-
cotropin release from superfused rat pituitary cells [5] and the pro-
opiomelanocortin gene expression in the mouse corticotrope-
derived cell line AtT20 [30, 31]. Intracerebroventricular and in-
tracisternal injection of PACAP also increases plasma vaso-
pressin secretion [32, 33]. PACAP is localized in nerve termi-
nals that innervate vasopressin-containing neurons, and PAC1 
receptor mRNA is highly expressed in vasopressin-containing 
neurons in the rat hypothalamic supraoptic nucleus [10]. In the 
posterior pituitary, PACAP stimulates the release of vasopressin 
through the cAMP signalling pathway [34]. Together, these data 
provide strong evidence that PACAP is involved in the activation of 
the HPA axis. 
  PACAP-deficient mice show a decrease in corticosterone secre-
tion in response to trimethyltin exposure [35], restraint stress [23], 
or light following constant darkness [36]. Corticosterone secretion 
elicited by restraint stress is more severely impaired in PACAP-
deficient mice, especially when the stress is prolonged [23]. The 
increase in hypothalamic mRNA expression of Egr1 (early growth 
response 1), c-Fos (FBJ osteosarcoma oncogene), and CRF seen 
with restraint stress, is much less pronounced in PACAP-deficient 
mice than in wild-type mice [23]. Taken together, these results 
suggest that PACAP plays an important role in the activation of 
hypothalamic neurons, in order to regulate the HPA axis response 
to stress. 
MECHANISTIC INSIGHTS INTO PACAP-DEPENDENT 
STRESS RESPONSES AND IMPLICATIONS FOR PSYCHI-
ATRIC DISORDERS 
  It has been demonstrated that intracerebroventricular injection 
of PACAP induces acute stress-related behaviors in rodents (e.g. 
body grooming and wet-dog shakes), which are associated with an 
elevation in plasma corticosterone levels and activation of cAMP 
response element-mediated CRF gene transcription [37]. 
  Intriguingly, chronic unpredictable stress dramatically increases 
mRNA expression of PACAP and brain-derived neurotrophic factor 
(BDNF) in the dorsal part of the BNST, a region of the central ex-
tended amygdala that mediates fear- and anxiety-like behavior. 
Moreover, intra-BNST infusion of PACAP induces an anxiogenic 
response [38]. These findings implicate PACAP in stress-induced 
increases in BNST neuroplasticity and in long-term stress-induced 
behavioral changes [39]. Since BDNF expression is stimulated by 
PACAP [40], and is decreased in PAC1 receptor-deficient mice 
[41], PACAP-stimulated BDNF expression may underlie the dorso-
lateral BNST cellular plasticity associated with anxiety and behav-
ior disorders [38,39]. Infusion of PACAP into the central nucleus of 
the amygdala has also been shown to induce stress-related behav-
iors [42]. 
  PACAP-deficient mice exhibit remarkable behavioral abnor-
malities, and can be regarded as an animal model of psychotic be-
havior and depression [43-46]. Genetic association studies have 
provided evidence that single nucleotide polymorphisms in the 
PACAP gene are associated with an increased risk for schizophre-
nia [47] or major depressive disorders [48]. In addition, PACAP 
increases expression of disrupted in schizophrenia 1 (DISC1), 
which is recognized as a leading candidate risk gene for schizo-
phrenia, and markedly but transiently decreases the association 
between DISC1 and the DISC1-interacting protein DBZ [49]. These 
data suggest that PACAP signaling might contribute to the patho-
genesis of psychiatric disorders. 
  It is widely accepted that inadequate response and/or prolonged 
exposure to stressors may result in psychiatric disorders [1-3]. It is 
therefore plausible that altered PACAP signaling systems may be 
involved in the etiology of stress-related psychiatric conditions. 
Maladaptive stress responses (either in hyperfunctional or hypo-
functional states), and subsequent development of disease symp-
toms, involve an interplay of genetic factors and environmental 
adversity during critical periods characterized by increased vulner-
ability to stressors [1-3]. Indeed, PACAP-deficient mice housed 
alone for a two-week period from 4-weeks of age are more aggres-
sive, but otherwise normal. Furthermore, correction of abnormal 
behavior by rearing mutant mice for 4 weeks in an enriched envi-
ronment is effective when carried out from 4-weeks of age, but is 
ineffective when carried out from 8-weeks of age [50]. 
  Finally, an important study by Ressler and colleagues [51] has 
shown a female-specific association of the PACAP–PAC1 receptor 
pathway with post-traumatic stress disorder (PTSD). Ressler et al. 
demonstrated that PTSD diagnosis was associated with peripheral 
blood levels of PACAP in females (higher levels in the PTSD co-
hort), and that an SNP in a putative estrogen response element of 
the PAC1 receptor gene, rs2267735, was associated with PTSD 
diagnosis, the severity of symptoms, and with PAC1 receptor mes-
senger RNA expression in the brain. In this report, they also re-
vealed that PACAP and PAC1 receptor mRNA levels were in-
versely correlated in the human cortex, suggesting that brain levels 
of PACAP peptide and PAC1 mRNA are tightly regulated [51]. In 
support, it has been shown that, in rat primary hippocampal neu-
rons, selective serotonin reuptake inhibitors up-regulate PACAP 
expression and down-regulate PACAP receptor (PAC1 and 
VPAC2) expression, while the tricyclic antidepressant imipramine 
shows an opposite effect [52]. In addition, in mice chronically 
treated with phencyclidine, an N-methyl-D-aspartic acid receptor 
antagonist, PACAP mRNA is reduced, while PAC1 receptor 
mRNA is increased in the frontal cortex [47]. These data suggest 
that the expression of PACAP peptide and PAC1 receptors are ac-
tively regulated under physiologic and pathologic conditions, and 
that perturbations in the PACAP–PAC1 pathway are involved in 
abnormal stress responses underlying psychiatric conditions such as 
PTSD [51]. 
CONCLUSIONS AND OUTLOOK 
  PACAP and its cognate receptors are widely expressed in brain 
regions and peripheral tissues known to be involved in the stress 
axes, and their expression levels may be dynamically altered under 
pathologic conditions. Convergent evidence implicates PACAP in 
stress-related responses, particularly during exposure to persistent 
stress. Under stressful conditions, PACAP coordinates stress signal-
ing in the central and peripheral nervous system [23], and probably 
acts in concert with other neurotransmitters and neurotrophins. It is 
intriguing that PACAP also acts on brain structures that mediate 
anxiety- and fear-related behaviors, where it may influence both 
hard-wired (genetically determined) stress responses and gene-
environment interactions in stress-related psychopathology. 
  The anxiogenic and/or fear-evoking properties of PACAP must 
be appropriate and controlled to enable development of a healthy 
stress response. Further study is required to establish how this neu-
ropeptidergic system is involved in psychopathology under condi-
tions of toxic stress (e.g. prolonged stress and emotional trauma). 
Future studies addressing the molecular basis and pathophysiologi-
cal implications of PACAP-dependent stress responses may facili-
tate the development of drug therapies for stress. 
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